• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sanofi throws hat in the ring with J&J’s in Actelion pursuit

December 6, 2016 By Sarah Faulkner

Sanofi throws hat in the ring with J&J's in Actelion pursuitSanofi (NYSE:SNY) is reportedly considering a bid for Actelion Pharmaceuticals (VTX:ATLN), competing with an offer made to the Swiss biotech by Johnson & Johnson (NYSE:JNJ). Bloomberg reported that Sanofi is working with advisers to assess its options and has made its interest known informally to Actelion. The French drugmaker has not made a formal comment on the matter and has not decided if it will move forward with a bid.

J&J has been in talks with Actelion about what reports have said may be a $27 billion takeover bid. The high premium offer is tempting to shareholders, who would rather take the cash now than bet on Actelion CEO Jean-Paul Clozel’s risky pipeline for therapeutics targeting rare diseases.

Actelion shares opened up by 4% and were trading at 207.30 Swiss francs in mid-morning activity today, up 2.3%.

Advisers for Sanofi have reportedly reached out to drugmakers Roche (PINK:RHHBY) and Pfizer (NYSE:PFE) to assess the potential interest for Actelion. Sanofi may be eager to compete for Actelion, since it lost out on a deal to buy Medivation Inc. earlier this year, which gave Pfizer a “blockbuster prostate cancer treatment”, according to Bloomberg. CEO Olivier Brandicourt said that the company would be ready to “act rather swiftly” should a new opportunity for acquisition arise.

J&J and Sanofi won’t have to worry about a counterbid from Novartis (NYSE:NVS), as CEO Joe Jimenez said in an interview this week that the Swiss drugmaker is looking for acquisitions of less than $5 billion.

For either company, closing a deal will mean winning over Clozel, who has repeatedly asserted his company’s independence. In 2011, the CEO and co-founder rallied shareholders against an investor’s plan to sell the firm and 4 years later, he fought off interest from drugmaker Shire.

“If I look at the (drugs) pipeline that Mr. Clozel is excited about, I am perhaps less excited about it and see perhaps a greater risk than reward,” Union Bancaire Privee fund manager Eleanor Taylor Jolidon told Reuters. Union Bancaire Privee is among the top 40 investors in Actelion and holds 0.23% of outstanding shares. Jolidon said than an offer of 250 francs per share would be very enticing and that if Clozel rejected the bid, then “he would have a lot of explaining to do.”

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Novartis, Pfizer Inc., Roche, Sanofi-Aventis

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS